Web page: https://itb.biologie.hu-berlin.de/
City: 10115 Berlin
Philippstr. 13, Haus 4
We are investigating liver metabolism and function with the help of computational models and methods. Read more about the LiSyM junior group at: https://www.livermetabolism.com
Junior Group Leader Dr. Matthias König
Institute for Theoretical Biology Humboldt-University Berlin Invalidenstraße 110, 10115 Berlin, Germany phone +49 30 2093-98435 email@example.com
The liver is the central metabolic organ of our body playing a crucial role in the clearance of drugs, xenobiotics and numerous ...
Former postdoc in the Theoretical Biophysics group headed by Edda Klipp at Humboldt-Universität zu Berlin and member of the LiSyM network, I am now an independent Group Leader at the Technical University of Munich focusing on developing an advanced bioinformatics toolbox for analyzing, integrating, and mining of various omics data in the context of precision medicine as well as molecular disease and patient subtyping.
Projects: LiSyM-Krebs Partneringhttps://orcid.org/0000-0003-2217-1655
Interested in modelling metabolism, predicting metabolic phenotypes and dynamic transitions in metabolism. Also using partially and incompletely characterized models (probabilistic predictions).
LiSyM-Krebs ist ein nationales Forschungsnetz zur Früherkennung und Prävention von Leberkrebs, das unter Verwendung des systemmedizinischen Forschungsansatzes die komplexen, dynamischen Prozesse der Krankheitsprogression analysiert, um ausgehend von den Erkenntnissen aus dem Forschungsnetz LiSyM die Entstehung von Leberkrebs besser zu verstehen, vorherzusagen und im besten Fall sogar zu verhindern.
Web page: Not specified
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
This generic project is intended to be a forum for all LiSyM partner and external stakeholders interested in participating in the BMBF initiative LiSyM-Krebs.
Organisms: Not specified
Disorders of the liver show up through changes in blood tests. These blood tests indicate markers for events taking place in the liver. Usually studies of liver tissue cannot be performed: as liver samples would need to be obtained through a liver biopsy, and this procedure is not without risk, therefore these samples are usually unavailable. Complex metabolism models based on existing and new scientific data can simulate changes in the liver caused by disease. They often reveal unknown relationships ...
Programme: LiSyM: Liver Systems Medicine
Start date: 1st Jan 2016
Organisms: Homo sapiens
One of the tasks of the healthy liver is to store fat. Yet, at some stage, too much fat makes the liver sick. One critical time point occurs when a healthy fatty liver becomes inflamed and progresses to steatohepatitis, or NASH. LiSyM-Pillar I will identify what events lead to this transition. Does it occur in all parts of the liver? Which molecules indicate that it is taking place? Can the degeneration be stopped or undone - and if so, how?
Dr. Matthias König (Humboldt University, Berlin) models the human liver on the computer. His simulations show the extent of individual differences in liver function and the external factors influencing it. König has shown that smoking falsifies the result of an important liver test (LiMAx). With his models, drug doses can be calculated so that they can be administered in doses that do not harm the liver.